Deals

News Photos

Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
Click on the image below to view in Stereo 3D

Lilly plans donation of 200,000 insulin KwikPens over next three years to support lower-income communities
Starting this month, Eli Lilly and Company (NYSE: LLY) will donate at least 200,000 KwikPens® to three relief organizations – Americares, Direct Relief and Dispensary of Hope – to stock insulin at nearly 200 U.S. free clinics through 2022. These donations will directly support lower-income people living with diabetes who qualify for free clinic services.
More Description
Image URL


Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) for selpercatinib (LOXO-292), for the treatment of patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer. The NDA is based on data from the LIBRETTO-001 Phase 1/2 trial in RET-altered lung and thyroid cancers. The FDA has filed the NDA and set a Prescription Drug User Fee Act (PDUFA) date in the third quarter of this year.
More Description
Image URL

 
 
 
vlrPhone
vlrFilter

Project of very low consumption, radiation and bitrate softphones, with the support of the spatial audio, of the frequency shifts and of the ultrasonic communications
Multifunction Audio Filter with Remote Control
More Information
Free the Animation VR
AR

Play to reveal 3D images and 3D models
More Information

WhmSoft Moblog
Copyright (C) 2006-2020 WhmSoft
All Rights Reserved